TrialBMC cancer2019

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.

Tsunekazu Mizushima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.